Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia [4]

American Journal of Hematology

Volumn 71, Issue 2, 2002, Pages 139-140

  Barton, James C ^a,b   Jones, Steven C ^a   Lamberth, Wade C ^a   Reymann, Michael T ^a   Scott, Varian C ^a  

^a Brookwood Medical Center Birmingham   (United States)

^b SOUTHERN IRON DISORDERS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; ASCITES; BODY WEIGHT DISORDER; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; DRUG WITHDRAWAL; EDEMA; HEART TAMPONADE; HUMAN; LETTER; MALE; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL;

EID: 0036786043     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10186     Document Type: Letter

References (5)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
2. th edition. New York: McGraw-Hill; 2001. p 2061-2085.
3. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gasmbacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
4. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
5. Novartis Oncology. Gleevec (imatinib mesylate). Full prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2002. p 1-32.